vs
Side-by-side financial comparison of Chemours Co (CC) and Steris (STE). Click either name above to swap in a different company.
Steris is the larger business by last-quarter revenue ($1.5B vs $1.3B, roughly 1.1× Chemours Co). Steris runs the higher net margin — 12.9% vs -3.5%, a 16.4% gap on every dollar of revenue. On growth, Steris posted the faster year-over-year revenue change (9.2% vs -2.1%). Steris produced more free cash flow last quarter ($199.5M vs $92.0M). Over the past eight quarters, Steris's revenue compounded faster (15.8% CAGR vs -1.2%).
The Chemours Company is an American chemical company that was founded in July 2015 as a spin-off from DuPont. It has its corporate headquarters in Wilmington, Delaware, United States. Chemours is the manufacturer of Teflon, the brand name of polytetrafluoroethylene (PTFE), known for its anti-stick properties. It also produces titanium dioxide and refrigerant gases.
Steris plc is an American-Irish-based medical equipment company specializing in sterilization and surgical products for the US healthcare system. Steris is operationally headquartered in Mentor, Ohio, and has been legally registered in Dublin, Ireland, for tax purposes since 2018. Previously the company was registered in the United Kingdom from 2014 to 2018.
CC vs STE — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.3B | $1.5B |
| Net Profit | $-47.0M | $192.9M |
| Gross Margin | 11.7% | 43.8% |
| Operating Margin | — | 18.3% |
| Net Margin | -3.5% | 12.9% |
| Revenue YoY | -2.1% | 9.2% |
| Net Profit YoY | -261.5% | 11.2% |
| EPS (diluted) | $-0.32 | $1.96 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.3B | $1.5B | ||
| Q3 25 | $1.5B | $1.5B | ||
| Q2 25 | $1.6B | $1.4B | ||
| Q1 25 | $1.4B | $1.5B | ||
| Q4 24 | $1.4B | $1.4B | ||
| Q3 24 | $1.5B | $1.3B | ||
| Q2 24 | $1.6B | $1.3B | ||
| Q1 24 | $1.4B | $1.1B |
| Q4 25 | $-47.0M | $192.9M | ||
| Q3 25 | $46.0M | $191.9M | ||
| Q2 25 | $-380.0M | $177.4M | ||
| Q1 25 | $-5.0M | $145.7M | ||
| Q4 24 | $-13.0M | $173.5M | ||
| Q3 24 | $-32.0M | $150.0M | ||
| Q2 24 | $60.0M | $145.4M | ||
| Q1 24 | $54.0M | $-1.4M |
| Q4 25 | 11.7% | 43.8% | ||
| Q3 25 | 15.6% | 44.2% | ||
| Q2 25 | 17.2% | 45.1% | ||
| Q1 25 | 17.3% | 43.3% | ||
| Q4 24 | 19.4% | 44.5% | ||
| Q3 24 | 19.0% | 43.6% | ||
| Q2 24 | 19.8% | 44.7% | ||
| Q1 24 | 20.9% | 40.2% |
| Q4 25 | — | 18.3% | ||
| Q3 25 | 2.5% | 18.2% | ||
| Q2 25 | -15.4% | 17.7% | ||
| Q1 25 | — | 14.6% | ||
| Q4 24 | -0.1% | 17.9% | ||
| Q3 24 | -2.1% | 16.5% | ||
| Q2 24 | 4.4% | 14.5% | ||
| Q1 24 | 5.1% | 22.0% |
| Q4 25 | -3.5% | 12.9% | ||
| Q3 25 | 3.1% | 13.1% | ||
| Q2 25 | -23.5% | 12.8% | ||
| Q1 25 | -0.4% | 9.8% | ||
| Q4 24 | -1.0% | 12.7% | ||
| Q3 24 | -2.1% | 11.3% | ||
| Q2 24 | 3.9% | 11.4% | ||
| Q1 24 | 4.0% | -0.1% |
| Q4 25 | $-0.32 | $1.96 | ||
| Q3 25 | $0.31 | $1.94 | ||
| Q2 25 | $-2.53 | $1.79 | ||
| Q1 25 | $-0.03 | $1.48 | ||
| Q4 24 | $-0.07 | $1.75 | ||
| Q3 24 | $-0.22 | $1.51 | ||
| Q2 24 | $0.39 | $1.46 | ||
| Q1 24 | $0.36 | $-0.02 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $670.0M | $423.7M |
| Total DebtLower is stronger | $4.1B | $1.9B |
| Stockholders' EquityBook value | $250.0M | $7.2B |
| Total Assets | $7.4B | $10.6B |
| Debt / EquityLower = less leverage | 16.40× | 0.27× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $670.0M | $423.7M | ||
| Q3 25 | $613.0M | $319.2M | ||
| Q2 25 | $502.0M | $279.7M | ||
| Q1 25 | $464.0M | $171.7M | ||
| Q4 24 | $713.0M | $155.2M | ||
| Q3 24 | $596.0M | $172.2M | ||
| Q2 24 | $604.0M | $198.3M | ||
| Q1 24 | $746.0M | $207.0M |
| Q4 25 | $4.1B | $1.9B | ||
| Q3 25 | $4.1B | $1.9B | ||
| Q2 25 | $4.1B | $1.9B | ||
| Q1 25 | $4.1B | $1.9B | ||
| Q4 24 | $4.1B | $2.0B | ||
| Q3 24 | $4.0B | $2.2B | ||
| Q2 24 | $4.0B | $2.2B | ||
| Q1 24 | $4.0B | $3.1B |
| Q4 25 | $250.0M | $7.2B | ||
| Q3 25 | $274.0M | $7.0B | ||
| Q2 25 | $228.0M | $7.0B | ||
| Q1 25 | $566.0M | $6.6B | ||
| Q4 24 | $571.0M | $6.4B | ||
| Q3 24 | $643.0M | $6.6B | ||
| Q2 24 | $714.0M | $6.4B | ||
| Q1 24 | $753.0M | $6.3B |
| Q4 25 | $7.4B | $10.6B | ||
| Q3 25 | $7.5B | $10.4B | ||
| Q2 25 | $7.5B | $10.4B | ||
| Q1 25 | $7.4B | $10.1B | ||
| Q4 24 | $7.5B | $10.0B | ||
| Q3 24 | $7.5B | $10.2B | ||
| Q2 24 | $7.2B | $10.1B | ||
| Q1 24 | $8.0B | $11.1B |
| Q4 25 | 16.40× | 0.27× | ||
| Q3 25 | 14.96× | 0.27× | ||
| Q2 25 | 17.99× | 0.27× | ||
| Q1 25 | 7.18× | 0.29× | ||
| Q4 24 | 7.11× | 0.32× | ||
| Q3 24 | 6.20× | 0.33× | ||
| Q2 24 | 5.53× | 0.35× | ||
| Q1 24 | 5.27× | 0.50× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $137.0M | $298.2M |
| Free Cash FlowOCF − Capex | $92.0M | $199.5M |
| FCF MarginFCF / Revenue | 6.9% | 13.3% |
| Capex IntensityCapex / Revenue | 3.4% | 6.6% |
| Cash ConversionOCF / Net Profit | — | 1.55× |
| TTM Free Cash FlowTrailing 4 quarters | $51.0M | $917.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $137.0M | $298.2M | ||
| Q3 25 | $146.0M | $287.8M | ||
| Q2 25 | $93.0M | $420.0M | ||
| Q1 25 | $-112.0M | $260.8M | ||
| Q4 24 | $138.0M | $332.8M | ||
| Q3 24 | $139.0M | $250.7M | ||
| Q2 24 | $-620.0M | $303.7M | ||
| Q1 24 | $-290.0M | $254.8M |
| Q4 25 | $92.0M | $199.5M | ||
| Q3 25 | $105.0M | $201.3M | ||
| Q2 25 | $50.0M | $326.4M | ||
| Q1 25 | $-196.0M | $189.9M | ||
| Q4 24 | $29.0M | $243.6M | ||
| Q3 24 | $63.0M | $148.8M | ||
| Q2 24 | $-693.0M | $195.7M | ||
| Q1 24 | $-392.0M | $163.3M |
| Q4 25 | 6.9% | 13.3% | ||
| Q3 25 | 7.0% | 13.8% | ||
| Q2 25 | 3.1% | 23.5% | ||
| Q1 25 | -14.3% | 12.8% | ||
| Q4 24 | 2.1% | 17.8% | ||
| Q3 24 | 4.2% | 11.2% | ||
| Q2 24 | -44.6% | 15.3% | ||
| Q1 24 | -28.8% | 14.6% |
| Q4 25 | 3.4% | 6.6% | ||
| Q3 25 | 2.7% | 5.9% | ||
| Q2 25 | 2.7% | 6.7% | ||
| Q1 25 | 6.1% | 4.8% | ||
| Q4 24 | 8.0% | 6.5% | ||
| Q3 24 | 5.0% | 7.7% | ||
| Q2 24 | 4.7% | 8.4% | ||
| Q1 24 | 7.5% | 8.2% |
| Q4 25 | — | 1.55× | ||
| Q3 25 | 3.17× | 1.50× | ||
| Q2 25 | — | 2.37× | ||
| Q1 25 | — | 1.79× | ||
| Q4 24 | — | 1.92× | ||
| Q3 24 | — | 1.67× | ||
| Q2 24 | -10.33× | 2.09× | ||
| Q1 24 | -5.37× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CC
| Titanium Technologies | $563.0M | 42% |
| Thermal And Specialized Solutions | $443.0M | 33% |
| Advanced Performance Materials | $312.0M | 23% |
| Other Non-Reportable Segment | $12.0M | 1% |
STE
| Servicerevenues | $404.7M | 27% |
| Consumablerevenues | $387.1M | 26% |
| Applied Sterilization Technologies | $286.6M | 19% |
| Capitalequipmentrevenues | $272.1M | 18% |
| Life Science | $145.8M | 10% |
